Roche’s Avastin receives EU approval for recurrent ovarian cancer treatment

The European Commission has given approval to Roche to use Avastin (bevacizumab) in combination with paclitaxel, topotecan or pegylated liposomal doxorubicin chemotherapy to treat women with recurrent ovarian cancer, which is resistant to platinum-co…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news